Molecular basis for the actions of Hsp90 inhibitors and cancer therapy

Journal of Antibiotics

Volumn 64, Issue 9, 2011, Pages 635-644

  Yamaki, Hiroshi ^a   Nakajima, Motowo ^b   Shimotohno, Kumiko W ^a   Tanaka, Nobuo ^b  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

cancer therapy; Hsp90 inhibitor; signal transduction pathway

Indexed keywords

3 (5 CHLORO 2,4 DIHYDROXYPHENYL) N ETHYL 4 (4 METHOXYPHENYL) 5 PYRAZOLECARBOXAMIDE; 4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; BIIB 021; CETUXIMAB; CNF 2024; CUDC 305; DNA METHYLTRANSFERASE 1; GENISTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEPARANASE; KF 25706; LAPATINIB; MACBECIN; MICRORNA; NOVOBIOCIN; PROTEIN P53; PU H71; QUERCETIN; RESORCINOL; RETASPIMYCIN; SNX 2112; SNX 5422; STA 9090; TANESPIMYCIN; TRANSCRIPTION FACTOR E2F; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 50589;

ANTIVIRAL ACTIVITY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIVISION; COLON CARCINOMA; DRUG MECHANISM; HUMAN; LUNG CARCINOMA; METASTASIS; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 80053357507     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.60     Document Type: Review

References (85)

1. Chen, B., Piel, W.H., Bruford, E. &Monterio, A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86, 627-637 (2005). (Pubitemid 41752943)
2. Caldenwood, S. K., Khaleque, M. A., Sawyer, D. B. &Ciocca, D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31, 164-167 (2006).
3. Bedin, M., Gaben, A. M., Saucier, C. &Mester, J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int. J. Cancer 109, 643-652 (2004). (Pubitemid 38405609)
4. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. &Neckers, L. Inhibition of heat-shock protein HSP90-pp60v-src hetero-protein complex formation by benzoquinoid ansamycins. Proc. Natl. Acad. Sci. USA 91, 8324-8328 (1994).
5. Stebbins, C. E. et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89, 239-250 (1997). (Pubitemid 27199896)
6. Pearl, L. H., Prodromou, C. &Workman, P. The Hps90 molecular chaperone: an open and shut case for treatment. Biochem. J. 15, 439-453 (2008). (Pubitemid 351429015)
7. Ratzke, C., Mickler, M., Hellenkamp, B., Buchner, J. &Hugel, T. Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc. Natl. Acad. Sci. USA 107, 16101-16106 (2010).
8. Hawle,P.et al. The middle domain of hsp90 acts as a discriminator between different types of client proteins. Mol. Cell. Biol. 26, 8385-8395 (2006). (Pubitemid 44748572)
9. Soti, C., Racz, A. &Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 277, 7066-7075 (2002). (Pubitemid 34953095)
10. Harris, K. F., Christensen, J. B., Radany, E. H. &Imperiale, M. J. Novel mechanisms of E2F induction by BK virus large-T antigen: requirement of both the pRb-binding and the J domains. Mol. Cell. Biol. 18, 1746-1756 (1998). (Pubitemid 28100940)
11. Gray-Bablin, J. et al. A redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA 95, 15215-15220 (1996).
12. Rustgi, A. K., Dyson, N. &Bernards, R. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene products. Nature 352, 541-544 (1991). (Pubitemid 21912380)
13. Gomez-Roman, N., Grandori, C., Eisenman, R. N. &White, R. J. Direct activation of RNA polymerase III by c-Myc. Nature 421, 290-294 (2003). (Pubitemid 36139136)
14. Yamaki, H. et al. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin and herbimycin, antibiotics of ansamycin group. J. Antibiot 49, 1021-1026 (1995).
15. Yamaki, H., Iguchi-Ariga, S. M. &Ariga, H. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin. J. Antibiot 42, 604-610 (1989).
16. Grandori, C. et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 7, 311-318 (2005). (Pubitemid 40331133)
17. Felton-Edkins, Z. A. et al. Direct regulation of RNA polymerase III by RB, p53 and c-Myc. Cell Cycle 2, 181-184 (2003).
18. Iguchi-Ariga, S. M. et al. An initiation site of DNA replication with transcriptional enhancer activity present upstream of the c-myc gene. EMBO J. 7, 3134-3142 (1988).
19. Zamore, P. D. &Haley, B. Ribo-gnome: the big world of small RNAs. Science 309, 1519-1524 (2005). (Pubitemid 41266468)
20. Bueno, M. J., Perez de Castro, I. &Malumber, M. Control of cell proliferation pathways by microRNAs. Cell Cycle 7, 3134-3148 (2008).
21. Reimer, D., Sadr, S. &Wiedemair, A. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann. N. Y. Acad. Sci. 1091, 270-281 (2006). (Pubitemid 47092243)
22. Christoffersen, N. R. et al. p53-independent upregulation of miR-34a during oncogeneinduced senescence represses MYC. Cell Death Differ. 17, 236-245 (2010).
23. Akao, Y., Nakagawa, Y. &Naoe, T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 29, 903-906 (2006).
24. Pare, J. M. et al. Hsp90 regulates the function of agronate 2 and its recruitment to stress granules and P-bodies. Mol. Biol. Cell 20, 3273-3284 (2009).
25. Carystinos, G. D., Kandouz, M., Alaoul-Jamali, M. A. &Batist, D. Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. Mol. Pharmacol. 63, 821-831 (2003). (Pubitemid 36368989)
26. Chiarugi, V. &Ruggiero, M. Role of three cancer 'master gene' p53, bcl2 and c-myc on the apoptotic process. Tumori 82, 205-209 (1996). (Pubitemid 26253707)
27. Miyata, Y., Ikawa, Y., Sibuya, M. &Nishida, E. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogenactivated protein kinase superfamily. J. Biol. Chem. 276, 21841-21848 (2001).
28. Miyata, Y. &Nishida, E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol. Cell. Biol. 24, 4065-4074 (2004). (Pubitemid 38496182)
29. Price, G. B. et al. Identification of a cis-element that determines autonomous DNA replication in eukaryotic cells. J. Biol. Chem. 278, 19649-19659 (2003). (Pubitemid 36799149)
30. Di Paola, D., Price, G. B. &Zannis-Hadjopoulos, M. Differentially active origins of DNA replication in tumor versus normal cells. Cancer Res. 66, 5094-5103 (2006). (Pubitemid 43844931)
31. Yamaki, H., Suzuki, H., Choi, E. C. &Tanaka, N. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin. J. Antibiot 35, 886-892 (1982). (Pubitemid 12023576)
32. Ozaki, A. et al. Complex formation between lamin A and the retinoblastoma gene product. Oncogene 9, 2649-2653 (1994).
33. McCabe, M. T., Davis, J. &Day, M. L. Regulation of DNA methyltransferase 1 by the pRb/E2F pathway. Cancer Res. 65, 3624-3632 (2005). (Pubitemid 40616339)
34. Zhou, Q., Agoston, A. T., Atadja, P., Nelson, W. G. &Davidson, N. E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol. Cancer Res. 6, 873-883 (2008).
35. Hellebreakers, D. M. et al. Angiostatic activity of DNA methytransferase inhibitors. Mol. Cancer Ther. 5, 467-475 (2006).
36. Li, C. et al. The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells. Oncogene 20, 8193-8220 (2001).
37. Jung, P., Menssen, A., Meyr, D. &Hermeking, H. Ap4 encodes a c-Myc-inducible repressor of p21. Proc. Natl. Acad. Sci. USA 105, 15046-15051 (2008).
38. Sain, N. et al. Potentiation of pacitaxel activity by HSP90 inhibitor 17-allylamino- 17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 5, 1197-1208 (2006). (Pubitemid 43881312)
39. Maloney, A. et al. Gene and protein expression profiling of human ovarian cancer cells treated with heat shock protein 90 inhibitor17-allylamino-17- demethoxygeldanamycin. Cancer Res. 67, 3239-3253 (2007). (Pubitemid 46724862)
40. Nobuhisa, T. et al. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci. 98, 535-540 (2007). (Pubitemid 46562744)
41. Huston, A. et al. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell toxicity in the bone marrow microenvironment. Clin. Cancer Res. 14, 865-874 (2008). (Pubitemid 351231171)
42. Koll, T. T. et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol. Cancer Ther. 7, 1985-1992 (2008).
43. Tsutsumi, S. et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell mobility and invasion. Oncogene 27, 2478-2487 (2008). (Pubitemid 351521101)
44. Soga, S. et al. KF25706, a noveloxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of HSP90 binding signaling molecules. Cancer Res. 59, 2931-2938 (1999). (Pubitemid 29283134)
45. Ikuina, Y. et al. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 46, 2534-2541 (2003). (Pubitemid 36637936)
46. Martin, C. J. et al. Molecular characterization of macbecin as an Hsp90 inhibitor. J. Med. Chem. 51, 2853-2857 (2008). (Pubitemid 351620806)
47. Zhang, M. Q. et al. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. J. Med. Chem. 51, 5494-5497 (2008).
48. Chandralpaty, S. et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 14, 240-248 (2008).
49. Okawa, Y. et al. SNX2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and hematologic tumors by abrogating signaling via Atk and ERK. Blood 113, 846-855 (2009).
50. Song, D. et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 7, 3275-3284 (2008).
51. Akiyama, T. et al. Genestein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem. 262, 5592-5595 (1987).
52. Basak, S., Pookot, D., Noonan, E. J. &Dahiya, R. Genestein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther. 7, 3195-3202 (2008).
53. Jeong, J. H., An, J. Y., Kwon, Y. T., Li, L. Y. &Lee, Y. J. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J. Cell Biochem. 105, 585-595 (2008).
54. Wu, L. X. et al. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl positive human leukemic blasts by novobiocin. Leukemia 22, 1402-1409 (2008). (Pubitemid 352006084)
55. Donelly, A. &Blagg, B. S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15, 2702-2717 (2008).
56. Radanyi, C. et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 274, 88-94 (2009).
57. Lin, T. Y. et al. The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tomors. Exp. Hematol. 36, 21266-21277 (2008).
58. Sharp, S. Y. et al. Inhibition of heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazol/isoxazole amide analogues. Mol. Cancer Ther. 4, 1198-1211 (2007). (Pubitemid 46711983)
59. Eccles, S. A. et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 66, 2850-2860 (2008). (Pubitemid 351556284)
60. Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 106, 8367-8373 (2009).
61. Bao, R. et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin. Cancer Res. 15, 4046-4057 (2009).
62. Zhang, H. et al. BIIB021, a synthetic HSP90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer 126, 1226-1234 (2010).
63. Boll, B. et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappa B and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin. Cancer Res. 15, 4046-4057 (2009).
64. McMillin, D. W. et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 69, 5835-5842 (2009).
65. Lang, S. A. et al. Targeting heat-shock protein 90 improve efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49, 523-532 (2009).
66. Shulte, T. W., Blugosklonny, M. V., Ingui, C. &Neckers, L. Disruption of the Raf-1- Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem. 270, 28654-28659 (1995).
67. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancer. Nat. Med. 14, 1315-1316 (2008).
68. Fujita, N., Sato, S., Ishida, A. &Tsuruo, T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 277, 10346-10353 (2002). (Pubitemid 34968152)
69. Chandralpaty, S. et al. Inhibitors of Hsp90 block p95-Her2 signaling in trastuzumabresistant tumors and suppress their growth. Oncogene 29, 325-334 (2010).
70. Leow, C. C. et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther. 8, 2131-2141 (2009).
71. Hu, X. F. et al. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J. Clin. Invest. 119, 362-376 (2009).
72. Imada, T. et al. Cox-2 induction by heparanase in the progression of breast cancer. Int. J. Mol. Med. 17, 221-228 (2006).
73. Nakajima, M. et al. Suramin, a potent inhibitor of melanoma heparanase and invasion. J. Biol. Chem. 266, 9661-9666 (1991). (Pubitemid 21906707)
74. Taldone, T., Gozman, A., Maharaj, R. &Chiosis, G. Targeting Hsp90: small molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370-374 (2008).
75. Ciardiello, F., De Vita, F., Ordituara, M., De Piasido, S. &Tortora, G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin. Emerg. Drugs 8, 501-514 (2003). (Pubitemid 37522662)
76. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45, 787-795 (2009).
77. Ju, H. Q. et al. Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. Bioorg. Med. Chem. Lett. 21, 1675-1677 (2011).
78. Vozzolo, L. et al. Gyrase, B inhibitor impairs HIV-1 replication. Curr. Opin. Invest. Drugs 9, 1287-1295 (2008).
79. Vendeville, A. et al. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol. Biol. Cell 15, 2347-2360 (2004). (Pubitemid 38580651)
80. Xu, Y. &Lindquist, S. Heat-shock protein HSP90 governs the activity of pp60v-src kinase. Proc. Natl. Acad. Sci. USA 90, 7074-7078 (1993). (Pubitemid 23222391)
81. Uehara, Y., Hori, M., Takeuchi, T. &Umezawa, H. Phenotypic change from transformed to normal by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Raus sarcoma virus. Mol. Cell. Biol. 6, 2198-2206 (1986). (Pubitemid 17189579)
82. Vojtechova, M., Senigl, F., Sloncova, E. &Tuhachova, Z. Regulation of c-Src activity by the expression of wild-type v-Src and its kinase-dead double Y416F-K295N mutant. Arch. Biochem. Biophys. 455, 136-143 (2006). (Pubitemid 44708845)
83. Cooper, J. A. The Src Family of Protein-Tyrosine Kinases. in Peptides and Protein Phosphorylation (ed. Kemp, B. E.) 85(CRC Press, Boca Raton, FL, 1991).
84. Ferracini, R. &Brruge, J. Analysis of mutant forms of the c-src gene product containing a phenylalanine substitution for tyrosine 416. Oncogene Res. 5, 205-219 (1990). (Pubitemid 20088244)
85. Azarnia, R., Reddy, S., Kmiecik, T. E., Shalloway, D. &Loewenstein, W. R. The cellular src gene product regulates junctional cell-to-cell communication. Science 239, 396-401 (1988).